Geopolitics and Science Funding for Universal Health Access

1. Introduction

Universal health access depends on more than the formal existence of services or the incorporation of new technologies. For a biomedical innovation to generate population-level benefit, it must pass through a sequence of stages that includes research funding, knowledge generation, technological development, scale-up, regulation, procurement, distribution, and use within health services (BONHAM; ALBERTI, 2017; CHORNIY et al., 2021). In this sense, the literature on universal coverage distinguishes nominal coverage from effective access and financial protection, emphasizing that the availability of technologies translates into benefit only when economic, territorial, organizational, and productive barriers are overcome (EVANS; HSU; BOERMA, 2013; CULYER; CHALKIDOU, 2019). This perspective shifts the analysis of innovation away from an isolated scientific output toward a process conditioned by institutions, financing, and implementation capacity.

The international distribution of this capacity is deeply asymmetric. Countries and regions differ in the availability of scientific infrastructure, human resources, competitive funding, industrial capacity, purchasing power, and integration into international research networks. Studies of inequalities in science funding and international collaboration indicate that the concentration of resources in certain countries can reinforce cumulative disparities in knowledge production and in the capacity to convert research into technological applications (PETERSEN, 2021; MCMANUS et al., 2020; RUEDIGER; RIS; IYER, 2025). For low- and middle-income countries, dependence on external financing, imported inputs, and unequal access to productive platforms may widen the gap between the global existence of a technology and its local availability. Therefore, discussions of health access must consider the geography of science funding and production, rather than focusing only on the clinical effectiveness of innovations.

International health financing is also sensitive to economic cycles, donor priorities, and changes in multilateral cooperation. The literature on development assistance for health shows that these flows are not homogeneous, vary across fields and countries, and are subject to changes in the political and economic priorities of funders (DIELEMAN et al., 2019; SCHÄFERHOFF et al., 2019; MOON; OMOLE, 2017; APEAGYEI et al., 2025). In systems that depend on external sources to expand service provision or acquire higher-cost technologies, fluctuations in these resources may affect program continuity, bargaining power, and planning capacity. The sustainability of access therefore cannot be assessed only by the volume of investment at a given moment, but also by resource predictability, domestic fiscal capacity, and the existence of local structures able to absorb investment and transform it into effective provision of health goods and services.

In this context, geopolitics operates through multiple mechanisms. Relations among states, multilateral organizations, companies, scientific institutions, and funders can affect research priorities, rules governing the circulation of knowledge, technology transfer, intellectual property protection, the location of production, and the organization of supply chains. Global health governance is therefore simultaneously technical and political: decisions on financing, international coordination, and resource distribution are made in environments where national interests, economic capabilities, and public-health objectives coexist and at times come into tension (FRENK; MOON, 2013; KICKBUSCH; LIU, 2022; GOSTIN; FRIEDMAN; FINCH, 2023). Health diplomacy and scientific cooperation can strengthen transnational coordination, but their effectiveness depends on institutional arrangements capable of balancing diverse interests while preserving shared health objectives.

The recent experience with vaccines made this tension particularly visible. During the COVID-19 pandemic, the initial concentration of manufacturing capacity and competition for dose procurement stimulated debate on vaccine nationalism, multilateral purchasing mechanisms, and distributive justice (FIDLER, 2020; YAMEY et al., 2020; YOO et al., 2022; PRIVOR-DUMM et al., 2023). This episode should not be treated as a universal model for all technologies, but it illustrates how industrial capacity, financing, contracts, logistics, and purchasing power can influence the speed of access even when the underlying scientific knowledge already exists. It also reinforces the importance of sustainable production capacity in low- and middle-income countries and of strategies that consider regional manufacturing, regulatory capacity, scale, and supply-chain stability (HAYMAN; KUMAR SURI; DOWNHAM, 2022).

Intellectual property and price formation add another layer to the problem. Patents, innovation incentives, public financing, and corporate strategies interact in complex ways in determining the final price of medicines and other technologies. The literature documents both the role of intellectual-property mechanisms in structuring incentives for research and controversies regarding their effects on access, particularly when ability to pay is limited or when essential technologies depend on a small number of suppliers (BEALL; BLANCHET; ATTARAN, 2017; BARIGOZZI; JELOVAC, 2020; CONTI; DAVID, 2020; SISMONDO, 2020; OKENIYI; OKEREKE, 2022). For this reason, a useful economic analysis must distinguish at least three dimensions: production cost, acquisition price, and implementation cost. These dimensions are related but not equivalent. A reduction in industrial cost may not be fully passed on to the purchaser, and an apparently cheaper acquisition may require infrastructure, storage, training, monitoring, or logistics that increase the total cost to the health system.

Brazil provides a particularly relevant institutional case for this discussion. The Unified Health System (Sistema Único de Saúde, SUS) was established on the principles of universality, comprehensiveness, and public responsibility, while operating in an environment marked by fiscal constraints, territorial inequalities, and partial dependence on imported technologies and inputs (PAIM et al., 2011; CASTRO et al., 2019; CRUZ; BARROS; SOUZA, 2022). Brazilian literature shows that access to medicines and financing capacity vary across levels of government and territories, demonstrating that a formal right must be supported by financing, management, and material availability (BARROS et al., 2017; MORAES et al., 2022; SILVA et al., 2024). This reality makes the SUS an appropriate reference for examining how decisions made in science policy, industry, and trade propagate through to everyday care.

The concept of the Health Economic-Industrial Complex (Complexo Econômico-Industrial da Saúde, CEIS) broadens this perspective by treating the productive, technological, and economic base as a constitutive element of a universal system's capacity to respond to health needs. Under this approach, production, innovation, and access are not independent fields: vulnerability in the supply of inputs, equipment, medicines, or vaccines can limit the system's operational autonomy, while productive and technological development policies can be oriented toward public-health needs (GADELHA, 2022; GADELHA et al., 2024). This does not imply advocating complete self-sufficiency or assuming that domestic production is always more efficient. The analytical task is to identify which dependencies are critical, which technologies justify strategic capabilities, and which forms of cooperation, technology transfer, or regional production offer the best balance among supply security, cost, and access.

On this basis, this article examines how geopolitical and fiscal conditions influence the conversion of investment in science into technologies that are effectively accessible to the population. The guiding proposition is that innovation policies designed only up to the technological-development stage tend to capture the determinants of access incompletely; incorporating financial sustainability, productive capacity, supply security, and real-world distribution conditions from the stage at which scientific priorities are defined may increase the likelihood that public investment is translated into health benefit. The objective is not to establish a single causal relationship between geopolitics and access, but to construct an analytical framework capable of connecting science funding, productive dependence, intellectual property, price formation, and implementation capacity. The SUS is used as a Brazilian institutional reference, with implications discussed for low- and middle-income countries without assuming equivalence among health systems.

2. Materials and Methods

This work was designed as an essay supported by a structured critical review of the literature and analysis of science, technology, and health policies. The methodological objective is not to estimate an aggregate effect or to produce an exhaustive systematic review, but to integrate heterogeneous evidence capable of explaining the mechanisms through which geopolitical and fiscal conditions may interfere with the conversion of scientific investment into effective access to health technologies. This approach is consistent with the nature of the guiding question, which spans different levels of analysis—science funding, global governance, industrial capacity, intellectual property, price formation, procurement, logistics, and implementation in health systems—and therefore cannot be adequately addressed through a single class of epidemiological or economic study design.

2.1. Study Design and Unit of Analysis

The unit of analysis is the chain connecting scientific investment to population access. For the purposes of this study, the chain was organized into five interdependent levels: (i) geopolitical and fiscal conditions; (ii) research financing and organization; (iii) productive and regulatory capacity; (iv) procurement, price formation, and supply; and (v) implementation and access within health services. The model begins from the premise that the presence of an innovation on the market is not, by itself, equivalent to its effective availability to the population, a distinction consistent with the literature on universal coverage and access (EVANS; HSU; BOERMA, 2013).

The analysis was designed to identify mechanisms and conditional relationships rather than to assume a linear causal relationship between geopolitics and health outcomes. Political or economic events are therefore interpreted as factors that may alter incentives, financial flows, input availability, bargaining power, the stability of productive chains, and implementation capacity. The interpretation recognizes that multilateral institutions, states, funders, companies, and scientific organizations operate within a governance system in which interests and capacities are unevenly distributed (FRENK; MOON, 2013; KICKBUSCH; LIU, 2022).

2.2. Bibliographic Corpus and Documentary Sources

The initial corpus consists of the 70 references assembled for this manuscript, covering literature on science funding, international health assistance, universal coverage, diplomacy and global governance, intellectual property, medicine prices, vaccine production, access to technologies, the SUS, and the Health Economic-Industrial Complex. The references were treated as an analytical support set previously selected for thematic relevance. Because the corpus was not originally assembled under a systematic-review protocol, no claims are made regarding exhaustiveness, independent dual screening, or a PRISMA flow diagram.

The temporal scope of the corpus is intentionally broad. Contemporary studies are prioritized for questions of financing, production, governance, and access, while earlier studies are retained when they provide historical or conceptual foundations necessary to understand the SUS, universal coverage, or incentives for innovation. Likewise, the English- and Portuguese-language literature is not assumed to represent the entirety of global scholarship; possible linguistic or regional gaps are treated as a limitation of the synthesis.

Official documents from multilateral organizations and public institutions may be incorporated when they constitute primary sources for policies, expenditure series, institutional definitions, or rules applicable to the period under analysis. In such cases, documentary evidence is distinguished from peer-reviewed literature. This separation avoids treating institutional statements, regulations, or administrative data as if they were efficacy studies or causal estimates.

2.3. Relevance Criteria and Thematic Classification

Sources in the corpus are classified according to their direct contribution to the guiding question. Six thematic domains were defined: (1) distribution and financing of scientific activity; (2) international and domestic health financing; (3) governance, diplomacy, and cooperation in global health; (4) intellectual property, innovation incentives, and price formation; (5) productive capacity, regional manufacturing, vaccines, and supply security; and (6) universal coverage, the SUS, and the economic-industrial base of health. Studies spanning more than one domain may be classified in a primary category and in secondary categories.

The relevance of each source is assessed by its ability to support at least one of the following analytical functions: describe a structural condition; document a mechanism; present empirical evidence on financing, production, or access; discuss a public-policy intervention; or provide a conceptual framework required for interpretation. Studies of collaboration and inequality in science funding, for example, inform the first level of the chain (PETERSEN, 2021; MCMANUS et al., 2020), while analyses of international health assistance inform the stability and distribution of global financial flows (DIELEMAN et al., 2019; APEAGYEI et al., 2025).

2.4. Structured Analytical Framework and Variables

To reduce impressionistic interpretation, the references were examined using a structured analytical framework. For each source, the analysis considered: authors and year; country, region, or population analyzed; study or document type; technology or health sector addressed; relevant geopolitical, fiscal, or institutional mechanism; source or modality of financing; stage of the productive or access chain involved; main indicator or outcome; economic definition used; limitations explicitly stated by the authors; and the specific contribution to the manuscript's argument. This framework guided the qualitative synthesis and did not generate a separate dataset.

Economic information is classified so that distinct concepts are not used interchangeably. Three minimum categories are preserved throughout the synthesis: production cost, understood as the resources used in manufacturing or provision; acquisition price, corresponding to the amount paid by the purchaser or system; and implementation cost, which includes infrastructure, storage, transport, training, quality control, administration, and other resources required to make the technology available within the service. Where relevant, budget impact and cost-effectiveness are treated as additional dimensions without being conflated with unit price. This distinction is consistent with the need to assess health investments in light of the real constraints and opportunities of health systems (CULYER; CHALKIDOU, 2019).

2.5. Structure of the Mechanism-Based Synthesis

The synthesis is conducted by tracing linked mechanisms. Rather than simply grouping studies that favor or oppose a particular policy, the analysis asks how an initial condition may propagate along the access chain. Fiscal constraint, for example, may alter science funding or purchasing capacity; productive concentration may increase vulnerability to supply disruptions; intellectual property and market structure may affect price and negotiation; and logistical requirements may modify total cost even when the acquisition price is reduced. A conclusion is considered more robust when different sources, using distinct designs, converge on the same mechanism without erasing their respective limitations.

Associations are described as associations and historical evidence as historical evidence. Causal inferences are used only when the design of the source or a coherent body of evidence permits such an interpretation. This rule is particularly important for topics such as pharmaceutical prices, public financing of innovation, and intellectual property, for which findings and arguments depend on the market, technology, and regulatory architecture under consideration (BEALL; BLANCHET; ATTARAN, 2017; BARIGOZZI; JELOVAC, 2020; CONTI; DAVID, 2020).

2.6. Production, Supply Chains, and Supply Security

The productive dimension is examined with a focus on the relationship among the geographic concentration of manufacturing, availability of critical inputs, regulatory capacity, scale, technology transfer, and continuity of supply. National or regional production is not assumed to be superior by definition. Each alternative must be interpreted in light of costs, minimum efficient scale, quality, supply stability, and the possibility of integration into international networks. The literature on sustainable vaccine manufacturing in low- and middle-income countries is used as a reference for discussing the conditions under which regional capacity may contribute to resilience and access, without turning self-sufficiency into an absolute objective (HAYMAN; KUMAR SURI; DOWNHAM, 2022).

2.7. The SUS as an Institutional Reference and International Comparability

The SUS is used as an institutional reference because it combines a universal mandate, decentralized public financing, pharmaceutical-assistance policies, and a long-standing agenda of productive development in health. The Brazilian analysis considers simultaneously the universal architecture of the system, documented financing constraints, and territorial inequalities (PAIM et al., 2011; CASTRO et al., 2019). The productive and technological base is interpreted through the concept of the Health Economic-Industrial Complex, which connects development, innovation, and health-response capacity (GADELHA, 2022; GADELHA et al., 2024).

Extrapolation to low- and middle-income countries is made by mechanism rather than by institutional equivalence. A result observed in Brazil is not assumed to be directly transferable to another health system. Comparisons are considered only when there is a relevant similarity in the mechanism under analysis—for example, dependence on imports, fiscal limitation, supplier concentration, or the need for regional productive capacity—and differences in coverage, financing, regulation, and market structure are made explicit.

2.8. Treatment of Heterogeneity, Uncertainty, and Economic Data

Heterogeneity across sources is treated as a characteristic of the object of study rather than as noise to be eliminated. Studies may examine different countries, periods, technologies, and indicators; therefore, monetary values or percentages are not directly combined when they do not share the same perspective, currency, base year, denominator, or cost definition. Whenever a quantitative comparison is used, the currency, value year, cost perspective, and unit of analysis should be recorded. Any conversions or updates of values should explicitly state the inflation index, exchange rate, or parity measure used.

Uncertainty is expressed through the quality and scope of the source, the degree of convergence among studies, and the sensitivity of the mechanism to context. Evidence from a single country or from exceptional situations such as the COVID-19 pandemic is used to illustrate plausible mechanisms but is not automatically generalized to all technologies or periods. This caution is necessary so that phenomena such as vaccine nationalism, international competition for inputs, or emergency purchasing mechanisms are not treated as universal patterns of health-market behavior.

2.9. Quality Control, Transparency, and Methodological Limitations

Manuscript quality control is based on traceability between claims and sources. Relevant factual statements should be linked to identifiable references, and each citation should be used within the scope actually studied by the original work. When a source is used as an example or conceptual foundation, that function should be distinguished from direct empirical evidence. Redundant references may be retained when they provide replication across different contexts, but they should not be accumulated merely to increase citation density.

This design has limitations. The 70-reference corpus is deliberately multidisciplinary and did not originate from a prospectively registered systematic search; it therefore does not permit claims of exhaustive literature coverage or calculation of formal measures of publication bias. Heterogeneity of study designs also precludes meta-analysis. In contrast, the adopted structure allows evidence from public health, health economics, science and technology, pharmaceutical production, and global governance to be integrated around the same hypothetical causal chain while keeping explicit the boundaries among description, association, interpretation, and normative proposition.

The final synthesis is considered satisfactory when each conclusion can be traced to a described mechanism, compatible evidence, and acknowledged limitations. Policy recommendations are presented as context-dependent options rather than as universally superior solutions. This principle is central to the objective of the work: to provide a useful framework for thinking about universal access without reducing institutional, economic, and technological diversity to a single decision rule.

2.10. Use of AI-Assisted Technology in Manuscript Preparation

During manuscript preparation, the authors used ChatGPT (OpenAI) for English-language translation, drafting support, structural editing, and editorial refinement. All scientific claims, cited sources, interpretations, and final wording were critically reviewed and verified by the authors, who take full responsibility for the content of the manuscript.

3. Analytical Synthesis and Discussion I: Geopolitics, Financing, and Productive Dependence

The literature reviewed indicates that the relationship between science and health access cannot be understood as an automatic sequence in which greater knowledge production leads linearly to the availability of technologies for the population. Between scientific discovery and the effective use of an intervention lie stages of financing, development, regulation, manufacturing, negotiation, procurement, logistics, and implementation. Each stage is sensitive to political and economic conditions. In this sense, geopolitics operates less as an isolated variable than as a set of forces capable of redistributing resources, productive capacities, scientific priorities, and bargaining power among countries and institutions (FRENK; MOON, 2013; KICKBUSCH; LIU, 2022; GOSTIN; FRIEDMAN; FINCH, 2023).

This perspective shifts attention from the simple volume of investment to the architecture that allows investment to be transformed into health benefit. Countries may have substantial scientific output and still depend on external inputs, industrial platforms, intellectual property, capital, or suppliers to convert knowledge into products available within the health system. Conversely, countries with lower domestic scientific output may expand access through international procurement, technology-transfer agreements, regional cooperation, or multilateral mechanisms. The central point is that scientific capacity is a necessary but insufficient dimension of health autonomy and security.

3.1. Inequality in Science Funding and the Definition of Research Agendas

The global distribution of science funding remains asymmetric, both among countries and across research fields. Petersen (2021) argues that persistent funding inequalities among regions constitute a structural problem for global science because they influence the capacity to build teams, maintain infrastructure, generate data, and compete within international networks. This asymmetry does not simply mean producing fewer articles or patents; it can also affect which problems are considered priorities and which populations are represented in research agendas.

Studies of research funding for neglected diseases and cancer illustrate the existence of thematic and geographic concentrations (MRAZEK; MOSSIALOS, 2003; BAI et al., 2016; LOUCAIDES et al., 2019; AFOLARANMI et al., 2025; VIRANI et al., 2024). Across these settings, research capacity is not distributed uniformly according to disease burden or social need. These studies do not establish that every funding difference is caused by geopolitics, but they demonstrate that knowledge production takes place within markedly unequal resource structures.

In the Brazilian case, international collaboration helps expand scientific reach, visibility, and connectivity, but it also reveals dependence on external flows and on networks whose stability may vary with political priorities and budget availability. McManus et al. (2020) document the relevance of financing and international collaboration to Brazilian science. From the perspective of this study, this finding matters because it indicates that scientific resilience depends not only on the excellence of individual groups but also on stable mechanisms of funding, infrastructure, and cooperation.

The distributive issue is also present within funding agencies themselves. Ruediger, Ris, and Iyer (2025) discuss strategies and challenges for making research funding more equitable. The contribution of this debate to the present analysis is both methodological and political: when resources are scarce, prioritization criteria are not neutral. They may favor fields with greater pre-existing competitive capacity, technologies with more evident economic returns, or already consolidated institutions, thereby generating cumulative cycles of advantage. For universal health systems, this dynamic matters because needs with high population impact do not always coincide with the areas of greatest commercial or scientific attractiveness.

3.2. Fiscal Constraints and Volatility in International Health Financing

The second mechanism is fiscal. The capacity to convert science into access depends on the budgetary space available not only for research but also for the incorporation, procurement, and maintenance of technologies. In countries with broad public systems, fiscal constraints may operate at several stages simultaneously: they compress science and technology funding, limit industrial investment, reduce purchasing power, and hinder expansion of the infrastructure required for implementation.

The literature on development assistance for health shows that international flows are relevant but subject to donor priorities and contextual changes. Dieleman et al. (2019) analyzed historical trends in health financing by G20 countries, while Schäferhoff et al. (2019) discussed broader trends in global health financing. Apeagyei et al. (2025) updated this debate by examining historical trends, recent cuts, and projections to 2030. Taken together, these studies support a cautious conclusion: for countries that depend substantially on external financing, resource predictability is part of health-planning capacity.

Vulnerability does not arise only from the total amount received. Ottersen et al. (2017) showed that multilateral and bilateral funders use different criteria when allocating assistance, and Moon and Omole (2017) discussed criticisms of and reform proposals for this system. During the pandemic, Woskie and Wenham (2024) observed changes in the direction of official development assistance, including donor concentration, earmarking, and the use of loans. These elements show that the origin, purpose, and conditions of financing can be as important as its nominal amount.

Moreover, the architecture of health assistance is multipolar. Studies of flows originating in India and of assistance directed to the Middle East and North Africa show that emerging countries also participate in this network and that patterns of cooperation vary regionally (MOITRA et al., 2022; ZHAO et al., 2020). This weakens a binary reading of the international system as an exclusive relationship between high-income donors and low-income recipients. For the argument developed here, the main point is that diversification of partners may increase cooperation options, but it also makes governance more complex and requires national capacity to coordinate priorities, contracts, and long-term sustainability.

3.3. Science Diplomacy, Global Governance, and Competition for Technologies

Global health operates within an institutional structure in which science, diplomacy, and security overlap. Frenk and Moon (2013) had already highlighted governance challenges arising from the multiplicity of actors and the absence of a central authority capable of coordinating national and global interests. Subsequent analyses have examined the roles and interactions of major global-health actors and institutions, including the WHO and the World Bank (WILLIAMS; WYNER, 2017; SINGH; RAVI, 2023; LANGE; VILLARREAL; BÄRNIGHAUSEN, 2023; GOSTIN; FRIEDMAN; FINCH, 2023; ZHENG; JIN, 2024). Kickbusch and Liu (2022) further described health diplomacy as a field in which power and governance are being reconstructed.

Science can serve as a mechanism of cooperation even in politically tense environments. The experience of GISAID is one example of how data-sharing arrangements can sustain international collaboration in disease surveillance and response (ELBE; BUCKLAND-MERRETT, 2017). Work on science diplomacy also suggests that research networks can preserve channels of dialogue and response capacity in contexts where traditional diplomatic relations are weakened (KEVANY, 2014; KILLEEN et al., 2018; HLASHWAYO, 2026). Scientific cooperation, however, does not eliminate disputes over ownership, priority of access, recognition, and control of strategic resources.

The COVID-19 pandemic made this tension particularly visible (HASSOUN, 2021; SHARUN; DHAMA, 2021; SHAO, 2025). Fidler (2020) described the political dimension of so-called vaccine nationalism; Yamey et al. (2020) advocated mechanisms to expand global vaccine access; and Yoo et al. (2022) analyzed the role of COVAX in seeking more equitable distribution. Privor-Dumm et al. (2023) broadened the discussion to equity and justice in access, while Turyasingura, James, and Vermund (2023) focused on specific challenges on the African continent. These studies converge in showing that scientific availability and the capacity to manufacture a vaccine do not guarantee distribution proportional to epidemiological need.

It is important, however, not to transform the COVID-19 experience into a universal model for all health markets. The pandemic combined a global emergency, simultaneous demand, initially limited supply, extraordinary public investment, and the high strategic value of vaccines and inputs. It therefore functions as a stress test that makes mechanisms of competition and cooperation visible, but it does not permit the inference that all pharmaceutical technologies are negotiated under the same conditions.

3.4. Intellectual Property, Market Structure, and Price Formation

Intellectual property is another link between innovation and access. Patents can create economic incentives for research and development by granting temporary exclusivity, but their effect on access depends on additional factors, including market structure, the existence of therapeutic alternatives, regulatory capacity, purchasing scale, and bargaining power. Beall, Blanchet, and Attaran (2017) showed that patents on essential medicines are also filed in developing countries, demonstrating that the issue of intellectual property is not restricted to high-income markets.

The literature reviewed also challenges simplified relationships between high prices and the financing of innovation. Conti and David (2020) discuss the role of public funding in research associated with pharmaceutical products and the question of whether taxpayers may finance different stages of the innovation cycle. Lazonick and Tulum (2024) question the idea that high medicine prices are, by themselves, explained by the need to sustain pharmaceutical innovation. These studies do not imply that private investment is dispensable; rather, they reinforce the need to distinguish funding sources, risks assumed, and mechanisms of value appropriation throughout development.

Economic models further show that research funding and price negotiation can interact. Barigozzi and Jelovac (2020) analyzed this relationship theoretically for new medicines. For the present article, the implication is that science policy and procurement policy should not be treated as entirely separate spheres. When the public sector funds research, participates in trials, provides infrastructure, guarantees demand, or negotiates large volumes, there are multiple points at which contractual design and public policy may influence final prices and conditions of access.

At the same time, the patent debate does not replace analysis of productive capacity. Even when a technology is not protected or when a license exists, quality manufacturing may require know-how, facilities, qualified suppliers, process validation, and regulatory compliance. Okeniyi and Okereke (2022), in discussing pharmaceutical patents and access in sub-Saharan Africa, reinforce the relevance of the issue, but the access problem itself requires intellectual property to be integrated with technological and industrial capacity. Sismondo (2020) further notes that access to medicines is also shaped by access to markets, indicating that price, availability, and commercial structure must be analyzed together.

3.5. Productive Dependence, Supplier Concentration, and Supply Security

Local or regional production appears in the literature as one possible response to supply vulnerability, particularly for vaccines and other strategic products. Sustainable manufacturing, however, depends on scale, predictable demand, regulatory capacity, access to inputs, and the maintenance of technical competencies. Hayman, Kumar Suri, and Downham (2022) emphasize that sustainable vaccine manufacturing in low- and middle-income countries requires a combination of market conditions, financing, technology, and long-term policies. Establishing productive capacity without ensuring demand, quality, and supply-chain integration may therefore generate economically fragile structures.

The case of messenger RNA vaccines illustrates how innovative platforms can reduce or reorganize some stages while introducing new bottlenecks. Rosa et al. (2021) identified challenges and constraints in mRNA vaccine manufacturing, showing that the speed of scientific development does not eliminate requirements for raw materials, equipment, process control, and distribution. This example reinforces the need to assess technologies according to total cost and supply-chain robustness rather than only the apparent cost of one production stage.

Supplier concentration may be efficient during periods of stability, but it also creates systemic risk when shocks affect a small number of producers or logistics routes. Supply security should therefore not be confused with autarky. A resilience strategy may combine domestic production, multiple suppliers, technology-transfer agreements, strategic stockpiles, and regional cooperation. The optimal composition depends on the product, the required scale, and the cost of maintaining idle capacity.

In Brazil, the concept of the Health Economic-Industrial Complex connects these factors to the design of the universal health system. Gadelha (2022) and Gadelha et al. (2024) argue that the economic and material base of health is a component of the capacity to guarantee access. This approach is particularly useful because it avoids artificially separating industrial policy from health policy: the availability of medicines, vaccines, diagnostics, and equipment depends on investment and production decisions made before a product enters health services.

3.6. Intermediate Implications for Converting Science into Access

The synthesis of this first part suggests four implications. First, science funding should be analyzed together with the capacity to absorb and transform knowledge. Systems that fund research but cannot sustain development, manufacturing, regulatory assessment, or procurement may capture only a fraction of the investment's potential benefit. Second, diversification of cooperation and suppliers may reduce vulnerabilities, although it entails coordination costs and does not eliminate technological dependencies.

Third, intellectual property, price, and production need to remain analytically distinct. A patent may influence competition and negotiation, but it does not by itself explain production cost or implementation cost. Likewise, domestic production does not automatically guarantee a lower price, and a reduced acquisition price does not ensure access when infrastructure, logistics, or human resources are insufficient.

Fourth, access-oriented innovation policies need to consider health-system design from the outset. In universal systems, the public purchaser, regulation, the care network, and industrial policy can act in coordination. The next section examines this possibility through the SUS, public financing, access to medicines, and inequalities in implementation. The aim is to assess under which conditions institutional capacity converts scientific and productive resources into real availability for the population, while explicitly recognizing the limits of transferring Brazilian conclusions to other contexts.

4. Analytical Synthesis and Discussion II: The SUS, Access, and Productive Capacity

The analysis developed in the previous section showed that access to health technologies depends on a chain connecting science funding, productive capacity, intellectual property, markets, public procurement, logistics, and implementation. In this second part of the discussion, the Unified Health System (SUS) is used as an institutional reference for observing how these mechanisms operate within a system that combines a legal commitment to universality, large population scale, federal decentralization, and strong interaction between public and private provision. The objective is not to present the Brazilian case as a model that can be automatically transferred elsewhere, but to use it as an analytical setting in which tensions among a universal right, fiscal constraints, productive dependence, and territorial inequality can be examined in an integrated manner (PAIM et al., 2011; CASTRO et al., 2019; ATUN et al., 2015).

This choice is consistent with the guiding question because it allows three levels that are often treated as equivalent to be distinguished: the formal existence of coverage, the availability of a technology within the system, and effective access by the individual. Evans, Hsu, and Boerma (2013) highlight the conceptual distinction between universal coverage and universal access; this distinction is particularly relevant in large systems where financial barriers may coexist with territorial, organizational, logistical, or informational barriers. The performance of a health-innovation policy therefore cannot be inferred solely from the incorporation of a technology or its presence on official lists; it must also be assessed by the system's capacity to distribute and use that technology in a timely and equitable manner.

4.1. The SUS as an Institutional Reference for Converting Innovation into Access

The development of the SUS established health as a right and organized a broad public network supported by shared responsibilities across different levels of government (PAIM et al., 2011; MACHADO, 2024). Historical literature describes substantial advances in coverage and service organization, while also documenting geographic inequalities, underfunding, and coordination difficulties across sectors and federal levels (PAIM et al., 2011; CASTRO et al., 2019). These elements make the Brazilian case especially useful for the present argument: a system may recognize universality as a principle and still face material constraints in transforming available technologies into uniform access.

Health-system reforms in Latin America also show that expanding coverage depends on institutional design, financing, and delivery capacity, not solely on the normative definition of rights (ATUN et al., 2015). Analytically, this means that biomedical innovation reaches users through institutions. The efficiency of this mediation depends on mechanisms for assessment, procurement, distribution, regulation, and organization of care. A clinically effective technology may have limited population impact if it is incorporated without infrastructure, trained professionals, a reliable supply chain, or recurrent financing.

The concept of health systems as complex systems reinforces this interpretation. Evans and Kieny (2017) propose a systems approach to universal health coverage in which isolated interventions interact with financing, the workforce, governance, and service delivery. For the present manuscript, the implication is that science and technology decisions should also be assessed for compatibility with the architecture of the system that will have to absorb them. The boundary between science policy and health policy is therefore functionally porous: choices made during research and development may create or reduce subsequent implementation costs.

4.2. Financing, Decentralization, and Inequalities in Capacity

Decentralization increases the ability to adapt policies to local needs, but it also exposes differences in the fiscal and administrative capacity of territories. Cruz, Barros, and Souza (2022), analyzing municipal financing of the SUS between 2004 and 2019, identified growth in local expenditure and greater fiscal dependence, particularly among smaller and lower-income municipalities. This finding is important because it shows that national availability of a technology does not guarantee homogeneous capacity to finance and operationalize it across all territories.

Fiscal pressures may also affect service provision and long-term investment simultaneously. Lima (2019) discussed the potential effects of austerity on the future of the SUS, while Castro et al. (2019) identified insufficient financing as one of the system's sustainability challenges. The literature does not support the conclusion that every limitation on access derives from fiscal constraint, but it does support the proposition that budgetary space conditions the speed, scale, and continuity with which policies can be implemented.

From the perspective of universal coverage, the health-financing transition requires redistribution mechanisms capable of protecting groups and territories with lower revenue-raising capacity (WITTER et al., 2017). Savedoff et al. (2012) emphasize that expansion toward universal coverage is also a political-economic process, and Tandon and Reddy (2021) discuss redistribution as a component of the financing transition. This point directly connects domestic political economy and access: macroeconomic shocks, changes in revenue, and budget competition alter the margin available for technology procurement, service expansion, and investment in strategic production.

Economic evaluation can support prioritization decisions but does not replace distributive choices. Culyer and Chalkidou (2019) highlight the role of economic evaluation in resource allocation on the path toward universal coverage. Within the present framework, cost-effectiveness and budget-impact analyses are necessary, but they should be interpreted together with implementation capacity, territorial equity, and supply security. An intervention with a favorable cost-effectiveness ratio may remain inaccessible if it requires high upfront investment, unavailable infrastructure, or logistics flows that are incompatible with local realities.

4.3. Access to Medicines and the Difference Between Formal Availability and Effective Access

Access to medicines provides a concrete example of the possible distance between formal coverage and effective acquisition. Barros et al. (2017) relate access to medicines to the institutionalization of pharmaceutical services, while Moraes et al. (2022) analyze public-policy coverage and the acquisition of medicines in Brazil. In both cases, access emerges as the result of multiple components: prescribing, financing, service organization, physical availability, and the user's ability to obtain the medicine.

More recent data reinforce the importance of social inequalities within this chain. Mujica, Bastos, and Boing (2024), analyzing the 2019 National Health Survey, found differences in access according to gender, race/skin color, socioeconomic condition, and territory. This finding is particularly relevant to the argument of this article because it shows that the existence of a universal system can reduce certain inequalities without eliminating them entirely. Evaluation of an innovation policy must therefore consider who reaches the technology and under what conditions, not only how many units were purchased or distributed.

Responsibility for financing medicines is also shared across levels of government. Silva et al. (2024) discuss responsibilities for medicine financing in Brazilian municipalities, indicating that the financial governance of access is distributed among institutional actors. This feature increases the importance of coordination and predictability: interruptions in transfers, procurement, or supply can appear to users as unavailability even when the technology is formally covered.

The international literature points to similar challenges. Duong et al. (2019) describe different stakeholder roles in facilitating access to medicines, and Gray and Suleman (2025) emphasize that monitoring access to essential medicines remains incomplete. Experiences such as that of Rajasthan, India, analyzed by Selvaraj et al. (2014), show that free-provision policies can expand access, but their effectiveness depends on financing, management, and availability. These studies do not make the contexts equivalent; they do, however, reinforce that access is an institutional and logistical function rather than an intrinsic property of the product.

4.4. Productive Capacity and the Health Economic-Industrial Complex

The Brazilian perspective of the Health Economic-Industrial Complex (CEIS) provides an explicit bridge among industrial policy, innovation, and universality. Gadelha (2022) argues that the economic and material base of health is a structural component of the SUS, while Gadelha et al. (2024) relate production and innovation to universal health access. The analytical value of this approach lies in treating productive capacity not merely as an economic objective but as a component of health-system resilience.

This interpretation is consistent with the problem of productive dependence discussed in the previous section. When medicines, vaccines, active ingredients, equipment, or critical inputs depend on a small number of external suppliers, geopolitical events, trade restrictions, exchange-rate crises, or logistical disruptions can affect price and availability. Domestic or regional production may reduce some of these risks, but it should not be assumed to be automatically cheaper or more efficient. The decision requires comparison of scale, quality, capital investment, demand stability, opportunity cost, and technological capacity.

For vaccines, Hayman, Kumar Suri, and Downham (2022) discuss conditions for sustainable manufacturing in low- and middle-income countries. Their analysis reinforces that productive capacity requires more than the physical transfer of equipment: it involves a qualified workforce, regulatory systems, quality, suppliers, predictable markets, and financial sustainability. This observation is central to avoiding an overly simplistic interpretation of autonomy. Health autonomy does not necessarily mean producing every component domestically, but rather reducing critical vulnerabilities through combinations of local production, diversified suppliers, strategic stockpiles, contracts, and technological cooperation.

The interaction between large-scale public systems and productive capacity can also create coordination instruments. Predictable public procurement, when associated with technical criteria and transparent governance, can reduce demand uncertainty and support production planning. However, the transfer of benefits to final prices and access is not automatic. It must be demonstrated through indicators of cost, availability, delivery time, quality, and population coverage. This caution preserves the distinction adopted throughout the article among production cost, acquisition price, and total implementation cost.

4.5. Cooperation, Technology Transfer, and Regional Production as Conditional Strategies

The literature on universal coverage and global financing suggests that international cooperation can expand capacities when it complements, rather than replaces, national institutions. Jamison et al. (2013) argued for the possibility of convergence in global health through investment and expansion of effective interventions, while IFeagwu et al. (2021), reviewing financing for universal coverage in sub-Saharan Africa, documented persistent challenges related to resource mobilization, pooling mechanisms, and financial protection. These findings reinforce that technological cooperation needs to be connected to financing and to the recipient system's absorptive capacity.

Technology transfer should therefore be treated as a process rather than as an event. To produce sustainable effects, it may involve workforce training, process validation, quality systems, access to inputs, regulatory competence, and capacity for technological updating. In biological products, maintaining comparability and quality after process changes is particularly important. This limits solutions based exclusively on rapid substitution of suppliers or production stages, but it also indicates where investments in capacity can generate long-term systemic returns.

Regional production may constitute an intermediate strategy between concentrated dependence and complete national self-sufficiency. In principle, regional markets can share infrastructure, increase scale, and diversify suppliers. Feasibility, however, depends on regulatory harmonization, contracts, intellectual property, logistics, and governance among countries. For this reason, the present work treats regional production and technology transfer as resilience hypotheses to be evaluated rather than as universally superior solutions.

4.6. An Integrated Framework Linking Science, Supply Security, and Universal Access

The evidence synthesis allows the conversion of science into access to be organized as a chain of six interdependent functions: definition of scientific priorities; financing of research and development; production or procurement capacity; regulation and negotiation; distribution and implementation; and effective population access. Weakness in any function may reduce the health return on investments made in earlier stages. The usefulness of this framework is to shift evaluation of innovation from a single indicator—such as publication, patenting, regulatory approval, or unit price—to the performance of the complete pathway to the user.

For universal systems, four questions can guide prospective assessment of a technology. First, does the innovation respond to a relevant health need or merely to a technological opportunity? Second, is there sufficient financial and productive capacity to sustain it at scale? Third, does the acquisition price adequately represent total implementation cost, including infrastructure, storage, training, monitoring, and losses? Fourth, does the organization of the system allow the intervention to reach the groups and territories with the greatest need? These questions do not replace formal regulatory or economic assessments, but they help integrate dimensions that are often analyzed separately.

The SUS case shows why this integration is necessary. A universal system can function simultaneously as funder, purchaser, provider, indirect regulator of demand, and implementation platform. This scale creates opportunities to align innovation with public need, but it also increases exposure to fiscal constraints, territorial inequalities, and supply failures. Access-oriented science policy therefore needs to consider from the outset who will finance the technology, how it will be produced or procured, what logistical requirements it will have, and what institutional capacities will be necessary for its use.

The main implication of this second part of the discussion is that supply security and universal access are not agendas separate from science policy. They function as performance criteria for innovation itself when the ultimate objective is to generate population health benefit. The following section consolidates the general implications, limitations, and research agenda while avoiding causal extrapolations beyond what the literature supports.

5. General Implications, Limitations, and Research Agenda

The synthesis developed in the preceding sections supports the view that converting scientific investment into effective health access depends on an architecture broader than the capacity to produce knowledge. Research funding, technological priorities, intellectual property, industrial capacity, public procurement, regulation, logistics, health-service financing, and territorial inequalities form a chain in which gains achieved at one stage can be neutralized by constraints at subsequent stages. An access-oriented science policy should therefore not assess success only through publication output, patenting, regulatory approval, or isolated reductions in unit cost; it should also consider whether a technology can be sustained, procured, distributed, and used at a scale compatible with population need (EVANS; KIENY, 2017; GADELHA, 2022; GADELHA et al., 2024).

This interpretation also avoids a false opposition between scientific excellence and economic responsibility. Financial sustainability need not be understood as an external limit imposed on science, but as a dimension of the design of technologies intended to produce population impact. Similarly, supply security does not mean complete self-sufficiency, and international cooperation does not necessarily imply dependence. The challenge is to identify combinations of financing, production, procurement, and cooperation that reduce vulnerabilities without sacrificing quality, innovation, or the capacity to respond to technological and epidemiological change.

5.1. Implications for Science Policy and Innovation Financing

The first implication is that the definition of scientific priorities should incorporate, from the outset, the feasibility of implementation in real health systems. International funding inequalities influence not only the quantity of research produced but also the capacity to maintain infrastructure, train teams, and participate in competitive scientific networks (PETERSEN, 2021; RUEDIGER; RIS; IYER, 2025). In resource-constrained countries, choosing among multiple research agendas has important opportunity costs: financing one platform, disease area, or infrastructure project means delaying or reducing investment in competing alternatives.

This observation does not imply subordinating all research to immediate returns. Basic research, laboratory capacity, and scientific training have strategic value that often emerges over long time horizons. However, for programs explicitly oriented toward public-health innovation, selection criteria can be enriched by jointly considering epidemiological relevance, technological maturity, total implementation cost, dependence on inputs, scalability, and the potential for distributive benefit. Such an approach reduces the risk of creating scientifically promising technologies whose adoption is later constrained by foreseeable production or financing barriers.

Public research funding is also connected to price formation and incentive design. Studies discussing interactions among research financing, price negotiation, and private returns from innovation show that the relationship between public investment and final price is not straightforward (BARIGOZZI; JELOVAC, 2020; CONTI; DAVID, 2020). For public systems, this suggests the value of greater traceability among forms of state support, intellectual-property conditions, supply commitments, and procurement strategies. The aim would not be to impose a single rule for sharing benefits, but to make more transparent the economic pathway linking public resources to the final availability of technologies.

5.2. Practical Criteria for Assessing Access-Oriented Innovation

The analysis developed in this study supports a set of criteria for the prospective assessment of technologies and innovation programs. These criteria do not constitute a validated regulatory instrument, but rather a conceptual structure for organizing multidimensional decisions. First, the health need to be addressed and the population potentially benefited should be established. Second, the robustness of the existing clinical or technological evidence should be identified. Third, production cost, likely acquisition price, and total implementation cost should be estimated separately. Fourth, dependencies involving suppliers, raw materials, platforms, and intellectual property should be examined. Fifth, the system's capacity to absorb the technology—including infrastructure, human resources, and logistics—should be assessed. Finally, distributive effects should be considered, because average adoption of a technology may conceal important differences in access among groups and territories (CULYER; CHALKIDOU, 2019; MUJICA; BASTOS; BOING, 2024).

These criteria reinforce the distinction between technical efficiency and effective access. An innovation may reduce manufacturing costs and still fail to generate savings for the system if it requires expensive infrastructure, expansion of cold-chain capacity, intensive training, additional monitoring, or equipment acquisition. Conversely, a technology with a higher unit cost may offer advantages if it reduces losses, simplifies administration, prevents hospitalizations, or expands coverage. Economic comparisons should therefore make explicit the analytical perspective, time horizon, and cost components included.

For vaccines and other biological products, productive capacity must be analyzed together with quality, stability, and manufacturing flexibility. Hayman, Kumar Suri, and Downham (2022) highlight challenges to sustainable vaccine manufacturing in low- and middle-income countries. The argument applies more broadly: diversification of production may increase resilience, but only when accompanied by technical competence, quality systems, economic scale, and predictable demand. Local production should therefore be assessed as a strategy conditioned by the product and context rather than as a self-sufficient objective.

5.3. Implications for International Cooperation and Global Health Governance

The second major implication is that international cooperation remains necessary even when countries seek greater technological autonomy. Research, surveillance, productive chains, and the circulation of knowledge are transnational, and global health governance involves multiple public, private, and philanthropic organizations (FRENK; MOON, 2013; GOSTIN; FRIEDMAN; FINCH, 2023). In this environment, resilience strategies should balance diversification of partners, national bargaining capacity, and the maintenance of channels for scientific cooperation.

Experience with data-sharing mechanisms and multilateral initiatives during emergencies demonstrates that cooperation can generate important collective goods, while also revealing tensions over access, priority, and distribution. The COVID-19 pandemic showed that scientific availability does not guarantee equitable access, particularly during periods of restricted supply (YAMEY et al., 2020; YOO et al., 2022; PRIVOR-DUMM et al., 2023). The most generalizable lesson is not that all technologies should be governed like pandemic vaccines, but that cooperation instruments should anticipate rules for access, production capacity, and mechanisms for periods of scarcity.

For middle-income countries, science diplomacy can contribute simultaneously to capacity building and diversification of dependencies. Brazil has a significant tradition of international collaboration in its scientific production (MCMANUS et al., 2020). The continuity of these networks, however, depends on financing, institutional stability, and the capacity to transform academic cooperation into durable competencies. Strategic partnerships are more robust when they include personnel training, access to infrastructure, knowledge transfer, transparent governance, and measurable capacity objectives, thereby avoiding evaluation of cooperation solely by the volume of resources or number of agreements.

5.4. Limitations of This Analysis

This article presents a structured critical review and a proposal for conceptual integration; it is not a systematic review, meta-analysis, or econometric study. The bibliography was selected to represent the main mechanisms related to the guiding question rather than to estimate aggregate effects. Consequently, the absence of an exhaustive search prevents inference regarding the relative frequency of findings in the literature or quantitative comparison of the strength of each mechanism.

A second limitation arises from the heterogeneity of the sources. The corpus includes studies on science funding, health systems, intellectual property, international assistance, vaccine manufacturing, access to medicines, and global governance, conducted across different periods and populations. This diversity is useful for constructing a broad framework but limits direct comparisons. Evidence produced during the COVID-19 pandemic, for example, was interpreted as a stress case for governance and supply rather than as evidence that non-emergency markets necessarily reproduce the same dynamics.

The SUS was used as an institutional reference rather than as a case sufficient for universal generalization. Health systems differ in financing, federal structure, industrial capacity, purchasing power, and organization of care. Proposals derived from the Brazilian context therefore require adaptation when applied to other countries. Likewise, the category of low- and middle-income countries encompasses heterogeneous economic and institutional realities; any operational analysis should preserve this diversity.

Finally, the study does not empirically estimate the causal effect of geopolitics on prices, financing, or access. Terms such as geopolitical fragmentation, dependence, and resilience are treated as analytical categories, and their measurement will require specific studies. This limitation is deliberate: the primary objective is to build a research architecture that allows relationships to be tested more precisely in future work while avoiding the conversion of plausible associations into presumed causality.

5.5. Research Agenda

The research agenda derived from this work can be organized into four complementary fronts. The first is quantitative: developing indicators capable of tracking the conversion of science funding into incorporated products, system availability, and population access. This would require integration of databases on funding, scientific output, intellectual property, regulatory registration, public procurement, prices, supply, and utilization, while respecting the time lags between stages.

The second front is comparative. Case studies of similar technologies could examine why some products achieve broad diffusion while others remain restricted despite favorable technical evidence. Comparisons across countries or regions could assess how market scale, industrial capacity, transfer agreements, regulation, and procurement architecture affect total cost and continuity of supply. Such designs could transform the proposed framework into empirically testable hypotheses.

The third front is prospective and involves scenario modeling. Strategic technologies could be evaluated under combinations of domestic production, regional production, diversified imports, and technology-transfer agreements. Outcomes should not be limited to the lowest unit price: replenishment time, supplier concentration, risk of disruption, initial investment requirements, and maintenance costs should be included in the resilience analysis. Studies of this type would be particularly useful for products exposed to supply shocks or high technological dependence.

The fourth front is distributive. National averages should be complemented by analyses of access according to territory, income, race/skin color, gender, and other dimensions relevant to each context. Brazilian literature on access to medicines demonstrates that universal policies can coexist with persistent inequalities (MORAES et al., 2022; MUJICA; BASTOS; BOING, 2024). Integrating these differences into innovation assessment is necessary so that efficiency gains are not automatically equated with equity gains.

These four fronts also provide a direct bridge to subsequent methodological work. While the present manuscript organizes the political, economic, and institutional determinants of access, later studies can test, in selected products, how changes in process design, logistics, and the use of analytical tools influence total cost, supply security, and implementation feasibility. This connection makes it possible to distinguish the macrostructural level from the technological level without treating them as independent dimensions.

6. Conclusions

The question guiding this work was how geopolitical and fiscal conditions influence the conversion of investment in science into technologies that are effectively accessible to the population. The literature analyzed indicates that this conversion is mediated by an institutional and economic chain: definition of priorities, research and development financing, production or procurement capacity, intellectual property and negotiation, regulation, logistics, health-service financing, and implementation. Producing knowledge or achieving regulatory approval are therefore necessary milestones but are insufficient to guarantee universal access.

Geopolitics influences this chain by altering the availability of financing, the composition of partnerships, supplier concentration, conditions of cooperation, and bargaining power. Its effects, however, are neither uniform nor deterministic. Dependence on imports may represent vulnerability for some products and efficiency for others; domestic production may increase resilience or generate high costs when scale is insufficient; and intellectual property may stimulate development while simultaneously limiting competition under specific circumstances. Analysis should therefore replace binary answers with contextual and measurable assessment.

The SUS demonstrates the importance of this integrated approach. Legal universality and large purchasing capacity create relevant instruments for aligning innovation with public need, but fiscal constraints, territorial inequalities, and productive dependence can reduce the conversion of available technology into effective access. The Health Economic-Industrial Complex provides a conceptual basis for bringing production, innovation, and health policy closer together, provided that outcomes are assessed not only through installed capacity but also through price, continuity of supply, quality, and population coverage (GADELHA, 2022; GADELHA et al., 2024).

The main proposition of this article is therefore that access and supply security should be incorporated as performance criteria for science policy from the stage at which innovation priorities are defined. For each technology, the challenge is to identify the combination of science, financing, production, cooperation, and system organization capable of maximizing health benefit in a sustainable manner. The value of this perspective lies not in offering a single solution for all countries, but in making explicit the points at which investments may lose their capacity to generate social value.

In an international environment marked by scientific interdependence, fiscal constraints, and supply-chain vulnerabilities, bringing science policy, health economics, and supply planning closer together becomes part of the strategy for universal access itself. Future studies should empirically test the proposed framework and determine the contexts in which regional production, technology transfer, supplier diversification, or new financing models generate measurable gains. The ultimate objective remains simple, although operationally complex: to ensure that the value produced by science reaches the population in the form of safe, sustainable, and effectively available technologies.